Evidence for platelet alphaIIb beta3 activation despite elevated cytosolic cAMP

Area of Science:

• Biochemistry
• Cell Biology
• Hematology

Background:

• Cyclic nucleotides, particularly cyclic adenosine monophosphate (cAMP), are established inhibitors of platelet aggregation.
• Platelet activation involves a complex cascade, including fibrinogen binding and aggregation, which can be modulated by various signaling pathways.

Purpose of the Study:

• To investigate whether the inhibitory effect of cAMP on platelet aggregation can be overcome.
• To explore the role of protein kinase C (PKC) activation in conjunction with G-coupled receptor or calcium influx signaling in bypassing cAMP-mediated inhibition.

Main Methods:

• Platelet aggregation assays were performed using various agonists such as U46619, convulxin, and OAG.
• The effects of cAMP analogues (dibutyryl cAMP, iloprost) were examined in combination with epinephrine or ionomycin.
• PKC inhibition was employed to assess its role in the observed aggregation responses.

Main Results:

• Concomitant activation of a G1-coupled receptor (epinephrine) or calcium influx (ionomycin) overcame cAMP-induced inhibition of platelet aggregation and fibrinogen binding.
• Platelet aggregation was restored in the presence of dibutyryl cAMP when U46619, convulxin, or OAG were combined with epinephrine.
• PKC activation was essential for overcoming cAMP-induced inhibition, as PKC inhibition prevented aggregation even with simultaneous receptor or calcium channel activation.

Conclusions:

• cAMP-induced inhibition of platelet aggregation can be effectively counteracted by simultaneously activating protein kinase C (PKC).
• This counteraction is dependent on the presence of an activated G1-coupled receptor or an induced calcium influx.
• These findings highlight a potential mechanism for modulating platelet activity in conditions where cAMP signaling plays a significant role.